Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company that works with leading researchers and institutions to accelerate the development of new
Ocean Biomedical Inc.
-(OCEA)
XNAS:OCEA
Ocean Biomedical’s breast cancer research uncovers new tumor suppression pathway for its proprietary antibody
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said that new findings, co-authored by the company’s scientific co-founder Jack A. Elias
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company focused on transforming biomedical inventions into cutting-edge therapies. The company develops novel therapies
Ocean Biomedical’s JV partner Virion presents positive oncology data at SITC 2023
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biotechnology company that works to accelerate the development and commercialization of discoveries from research universities and
Ocean Biomedical’s chief scientist Dr. Jonathan Kurtis receives Falk Award for malaria drug candidate
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its chief scientist, Jonathan Kurtis MD, PhD has received the prestigious Falk
Ocean Biomedical forms JV with Virion Therapeutics to find treatments for cancer and chronic infectious diseases
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) entered into a joint venture with Virion Therapeutics, LLC, to expedite and expand the latter’s
Ocean Biomedical announces loan commitment of up to $10 million from largest stockholder
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers to develop and commercialize their discoveries,
Ocean Biomedical’s cancer-targeting antibody candidate shows effective tumor reduction against a subset of NSCLC with EGFR mutations
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biotechnology company that operates by partnering with leading researchers to accelerate new discoveries in the healthcare
Ocean Biomedical (OCEA) announces new patent for anti-fibrosis discovery
Ocean Biomedical, Inc. (NASDAQ: OCEA), a leading biopharma company that works to accelerate the development and commercialization of scientifically compelling assets from
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company that operates by partnering with leading researchers to accelerate new discoveries in the
Ocean Biomedical provides update on programs in malaria, fibrosis, and multiple cancers
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday provided an update on its broad range of programs in malaria, fibrosis, and multiple cancers.
Ocean Biomedical’s share price target averages $18.21 amid continued progress in research programs
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday shared collective analyst research coverage from three firms, with current Buy recommendations and share price
Ocean Biomedical shares details of its successful lung cancer program on World Lung Cancer Day
Biopharmaceutical company Ocean Biomedical, Inc. (NASDAQ: OCEA) provided details of its multi-pronged lung cancer program built on novel immunotherapy discoveries by the
Ocean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it is focusing its multi-pronged malaria program to address the chronic malaria
Ocean Biomedical (OCEA) joins the Russell 2000 Index
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market Russell 3000
Ocean Biomedical granted US patent for bispecific cancer immunotherapy treatment
Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Monday said its scientific co-founder Dr. Jack Elias has been granted a new, broad
Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice from the
Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock to $17.63
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific
Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business